• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

New ACC/AHA Hypertension Guidelines: How Have They Changed the Prevalence of Isolated Diastolic Hypertension in the United States?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The new 2017 ACC/AHA hypertension definition lowered the diastolic BP threshold to 80 mm Hg, changing the definition of isolated diastolic hypertension (IDH)
  • McEvoy et al. (JAMA, 2020)
    • Compared the prevalence of IDH in the United States, by 2017 ACC/AHA and 2003 Joint National Committee (JNC7) definitions

METHODS:

  • Cross-sectional and longitudinal analyses
  • Data sources
    • Cross-sectional analyses
      • National Health and Nutrition Examination Survey (NHANES 2013 to 2016)
    • Longitudinal analyses
      • Atherosclerosis Risk in Communities (ARIC) Study (baseline 1990 to 1992, with follow-up through December 31, 2017)
    • External cohorts for validation
      • NHANES III (1988 to 1994) and NHANES (1999 to 2014)
      • Give Us a Clue to Cancer and Heart Disease (CLUE) II cohort (baseline 1989)
  • Exposures
    • IDH as defined by 2017 ACC/AHA
      • Systolic BP <130 mm Hg, diastolic BP ≥80 mm Hg
    • IDH as defined by JNC7
      • Systolic BP <140 mm Hg, diastolic BP ≥90 mm Hg
  • Primary outcomes
    • Prevalence of IDH
    • Prevalence of US adults recommended BP pharmacotherapy by the 2017 ACC/AHA guideline based solely on the presence of IDH
    • Risk of incident atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) in the ARIC Study

RESULTS:

  • 9590 adults from the NHANES study | 8703 adults from the ARIC Study
    • NHANES
      • Mean baseline age 49.6 years; 52.3% women
    • ARIC
      • Mean baseline age 56.0 years; 57.2% women
  • Estimated prevalence of IDH
    • By 2017 ACC/AHA standards: 6.5%
    • By JNC7 standards: 1.3%
    • Absolute difference 5.2% (95% CI, 4.7 to 5.7%]
  • Among those newly classified 2017 standards
    • Met criteria for antihypertensive therapy: 0.6% (95% CI, 0.5 to 0.6%)
  • IDH as defined by the 2017 standards was not significantly associated with
    • ASCVD
      • Hazard ratio (HR) 1.06 (95% CI, 0.89 to 1.26)
      • 1386 events; median follow-up 25.2 years
    • HF
      • HR 0.91 (95% CI, 0.76 to 1.09)
      • n = 1396 events
    • CKD
      • HR 0.98 (95% CI, 0.65 to 1.11)
      • n = 2433 events
  • IDH as defined by 2017 standards was also not significantly associated with cardiovascular mortality in the 2 external cohorts
    • NHANES
      • HR 1.17 (95% CI, 0.87 to 1.56); n = 1012 events
    • CLUE II
      • HR 1.02 (95% CI, 0.92 to 1.14); n = 1497 events

CONCLUSION:

  • Under the 2017 ACC/AHA guidelines, the estimated prevalence of IDH was higher in the adult US population than it was under the JNC7 guideline
  • However, IDH using the new threshold was not associated with an increased risk of worse cardiovascular outcomes
  • The authors state

…the above results, demonstrating that diastolic BPs between 80 and 90 mm Hg have no adverse prognostic significance when systolic BP is well controlled, appear to be supported indirectly by other observational data

Learn More – Primary Sources:

Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes

Now You Can Get Mobile-Friendly ObG Clinical Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

The Latest ACC/ AHA BP Category Guidelines and Risk of Hypertensive Disorders of Pregnancy
ACC/AHA Blood Pressure Guideline: Current Classification System and Treatment Targets
New ACC Blood Pressure Guidelines in Pregnancy: Should We Start Monitoring Prior to 140/90?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site